Market Overview:
The global T cell surface glycoprotein CD4 market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of HIV and AIDS, rising demand for better treatment options, and growing investments in R&D for novel therapies. The global T cell surface glycoprotein CD4 market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into forigerimod acetate, HIV vaccine 2 (bivalent rgp120/MF59), ibalizumab (T-20), and others. On the basis of application, the market is segmented into HIV infection & AIDS therapy; graft versus host disease (GVHD) therapy; severe acute respiratory syndrome (SARS) therapy; and others. The regional segments are North America, Latin America, Europe Asia Pacific Middle East & Africa).
Product Definition:
CD4 is a glycoprotein found on the surface of T cells. It is important for the activation and function of T cells.
Forigerimod Acetate:
Forigerimod acetate is a small molecule that acts as an immunosuppressive agent. It decreases the immune response to cancer cells by decreasing antigen presentation and antibody responses. Forigerimod acetate has been shown to enhance T-cell function in vitro and in vivo, which may be attributed to its anti-cancer activity.
HIV Vaccine 2:
HIV-1 is the virus that causes Acquired Immunodeficiency Syndrome or Aids. There are more than 100 million people infected with HIV across the globe and around 5 million people are living with HIV infection. The only treatment for HIV at present is Antiretroviral Therapy (ART). However, there are no permanent cure for AIDS as of now and it can be treated but cannot be cured completely.
Application Insights:
The global market for T cell surface glycoprotein CD4 is categorized based on application into HIV, AIDS, graft versus host disease (GVHD), SARS-CoV-2 infection, and others. The other applications segment includes research studies and drug development. In 2017, the HIV segment dominated the overall market in terms of revenue share at over 40%. This can be attributed to high usage of cell therapies to treat people with AIDS as well as an increase in prevalence of HIV across the globe.
Treatment with antiretroviral therapy (ART) has led to a significant reduction in mortality due largely to improved quality of life among patients suffering from AIDS since 1996. However, treatment costs are also an important factor that must be considered while developing any healthcare plan for such patients which further hampers their access to care globally.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a substantial number of players, increasing focus on HIV vaccine development, and rising incidence of SARS-CoV infections. The region is expected to maintain its dominance throughout the forecast period owing to ongoing efforts by key players for commercialization and distribution of their products at affordable prices.
Asia Pacific is anticipated to witness lucrative growth over the forecast period due to growing awareness about HIV/AIDS infection among people & animals as well as continuous R&D activities undertaken by various organizations for development of effective treatment methods & vaccines against this virus.
Growth Factors:
- Increasing incidence of HIV/AIDS and other infectious diseases: The global T Cell Surface Glycoprotein CD4 market is expected to grow at a CAGR of over 7% during the forecast period owing to the increasing incidence of HIV/AIDS and other infectious diseases.
- Rising demand for T cell therapies: The growing demand for T cell therapies is another key factor driving the growth of the global T Cell Surface Glycoprotein CD4 market.
- Technological advancements in diagnostics and therapeutics: Technological advancements in diagnostics and therapeutics are aiding in better detection and treatment of various diseases, thereby propelling the growth of the global T Cell Surface Glycoprotein CD4 market.
- Growing awareness about immunology: There is a growing awareness about immunology among people, which is resulting in an increase in research activities related to this field, thereby fuelling the growth of the global T Cell Surface Glycoprotein CD4 market. 5) Rising number of cancer patients: The rising numberof cancer patients acrossthe globeis also contributingtothegrowthoftheglobalTCellSurfaceGlycoproteinCD 4market
Scope Of The Report
Report Attributes
Report Details
Report Title
T Cell Surface Glycoprotein CD4 Market Research Report
By Type
Forigerimod Acetate, HIV Vaccine 2, Ibalizumab, Others
By Application
HIV, AIDS, GVHD, SARS, Others
By Companies
Biotest AG, Bristol-Myers Squibb Co, CEL-SCI Corp, Fountain Biopharma Inc, Immupharma Plc, Sanofi, TaiMed Biologics Inc, United Biomedical Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
237
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global T Cell Surface Glycoprotein CD4 Market Report Segments:
The global T Cell Surface Glycoprotein CD4 market is segmented on the basis of:
Types
Forigerimod Acetate, HIV Vaccine 2, Ibalizumab, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
HIV, AIDS, GVHD, SARS, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Biotest AG
- Bristol-Myers Squibb Co
- CEL-SCI Corp
- Fountain Biopharma Inc
- Immupharma Plc
- Sanofi
- TaiMed Biologics Inc
- United Biomedical Inc
Highlights of The T Cell Surface Glycoprotein CD4 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Forigerimod Acetate
- HIV Vaccine 2
- Ibalizumab
- Others
- By Application:
- HIV
- AIDS
- GVHD
- SARS
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the T Cell Surface Glycoprotein CD4 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
T Cell Surface Glycoprotein CD4 is a protein that is found on the surface of T cells. It helps to bind to specific molecules, such as antigens, and it can help the T cell to attack and destroy infected cells.
Some of the major companies in the t cell surface glycoprotein cd4 market are Biotest AG, Bristol-Myers Squibb Co, CEL-SCI Corp, Fountain Biopharma Inc, Immupharma Plc, Sanofi, TaiMed Biologics Inc, United Biomedical Inc.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. T Cell Surface Glycoprotein CD4 Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. T Cell Surface Glycoprotein CD4 Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. T Cell Surface Glycoprotein CD4 Market - Supply Chain
4.5. Global T Cell Surface Glycoprotein CD4 Market Forecast
4.5.1. T Cell Surface Glycoprotein CD4 Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. T Cell Surface Glycoprotein CD4 Market Size (000 Units) and Y-o-Y Growth
4.5.3. T Cell Surface Glycoprotein CD4 Market Absolute $ Opportunity
5. Global T Cell Surface Glycoprotein CD4 Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. T Cell Surface Glycoprotein CD4 Market Size and Volume Forecast by Type
5.3.1. Forigerimod Acetate
5.3.2. HIV Vaccine 2
5.3.3. Ibalizumab
5.3.4. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global T Cell Surface Glycoprotein CD4 Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. T Cell Surface Glycoprotein CD4 Market Size and Volume Forecast by Application
6.3.1. HIV
6.3.2. AIDS
6.3.3. GVHD
6.3.4. SARS
6.3.5. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global T Cell Surface Glycoprotein CD4 Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. T Cell Surface Glycoprotein CD4 Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global T Cell Surface Glycoprotein CD4 Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. T Cell Surface Glycoprotein CD4 Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global T Cell Surface Glycoprotein CD4 Demand Share Forecast, 2019-2026
9. North America T Cell Surface Glycoprotein CD4 Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America T Cell Surface Glycoprotein CD4 Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America T Cell Surface Glycoprotein CD4 Market Size and Volume Forecast by Application
9.4.1. HIV
9.4.2. AIDS
9.4.3. GVHD
9.4.4. SARS
9.4.5. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America T Cell Surface Glycoprotein CD4 Market Size and Volume Forecast by Type
9.7.1. Forigerimod Acetate
9.7.2. HIV Vaccine 2
9.7.3. Ibalizumab
9.7.4. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America T Cell Surface Glycoprotein CD4 Demand Share Forecast, 2019-2026
10. Latin America T Cell Surface Glycoprotein CD4 Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America T Cell Surface Glycoprotein CD4 Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America T Cell Surface Glycoprotein CD4 Market Size and Volume Forecast by Application
10.4.1. HIV
10.4.2. AIDS
10.4.3. GVHD
10.4.4. SARS
10.4.5. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America T Cell Surface Glycoprotein CD4 Market Size and Volume Forecast by Type
10.7.1. Forigerimod Acetate
10.7.2. HIV Vaccine 2
10.7.3. Ibalizumab
10.7.4. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America T Cell Surface Glycoprotein CD4 Demand Share Forecast, 2019-2026
11. Europe T Cell Surface Glycoprotein CD4 Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe T Cell Surface Glycoprotein CD4 Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe T Cell Surface Glycoprotein CD4 Market Size and Volume Forecast by Application
11.4.1. HIV
11.4.2. AIDS
11.4.3. GVHD
11.4.4. SARS
11.4.5. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe T Cell Surface Glycoprotein CD4 Market Size and Volume Forecast by Type
11.7.1. Forigerimod Acetate
11.7.2. HIV Vaccine 2
11.7.3. Ibalizumab
11.7.4. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe T Cell Surface Glycoprotein CD4 Demand Share, 2019-2026
12. Asia Pacific T Cell Surface Glycoprotein CD4 Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific T Cell Surface Glycoprotein CD4 Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific T Cell Surface Glycoprotein CD4 Market Size and Volume Forecast by Application
12.4.1. HIV
12.4.2. AIDS
12.4.3. GVHD
12.4.4. SARS
12.4.5. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific T Cell Surface Glycoprotein CD4 Market Size and Volume Forecast by Type
12.7.1. Forigerimod Acetate
12.7.2. HIV Vaccine 2
12.7.3. Ibalizumab
12.7.4. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific T Cell Surface Glycoprotein CD4 Demand Share, 2019-2026
13. Middle East & Africa T Cell Surface Glycoprotein CD4 Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa T Cell Surface Glycoprotein CD4 Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa T Cell Surface Glycoprotein CD4 Market Size and Volume Forecast by Application
13.4.1. HIV
13.4.2. AIDS
13.4.3. GVHD
13.4.4. SARS
13.4.5. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa T Cell Surface Glycoprotein CD4 Market Size and Volume Forecast by Type
13.7.1. Forigerimod Acetate
13.7.2. HIV Vaccine 2
13.7.3. Ibalizumab
13.7.4. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa T Cell Surface Glycoprotein CD4 Demand Share, 2019-2026
14. Competition Landscape
14.1. Global T Cell Surface Glycoprotein CD4 Market: Market Share Analysis
14.2. T Cell Surface Glycoprotein CD4 Distributors and Customers
14.3. T Cell Surface Glycoprotein CD4 Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Biotest AG
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Bristol-Myers Squibb Co
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. CEL-SCI Corp
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Fountain Biopharma Inc
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Immupharma Plc
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Sanofi
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. TaiMed Biologics Inc
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. United Biomedical Inc
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook